Terrie Kellmeyer was named Chief Executive Officer of Anavex Life Sciences Corp. As of November 6, 2026, Anavex Life Sciences Corp. has reported 4 leadership change filings to the SEC under Item 5.02 of Form 8-K, from May 6, 2026 to November 3, 2026, naming 3 appointments and 1 departure (Form 8-K, November 3, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Anavex Life Sciences Corp? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: In · Person: Terrie Kellmeyer · Role: Chief Executive Officer · 8-K, 2026-11-03
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-11-02
- · In / out: Out · Person: Felix Lauscher · Role: Chief Executive Officer · 8-K, 2026-05-15
- · In / out: In · Person: Terrie Kellmeyer · Role: Chief Executive Officer · 8-K, 2026-05-06
Anavex Life Sciences Corp. reported changes in 4 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-05-06 to 2026-11-03. They name 2 people, with 3 appointments and 1 departure. Every row below is cited to the filing it comes from, and this page adds each new change as Anavex Life Sciences Corp. files it.
Also on the record for Anavex Life Sciences Corp.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| July 31, 2026 | Stake report, Schedule 13G, by Vanguard Capital Management | 5.03% of the class | 5%+ stakes | Source |
| March 26, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
Selling to them or working with them? See who runs Anavex Life Sciences Corp. now and the warning signs.
Free to see. No signup.
Keep reading
More on Anavex Life Sciences Corp. and the records around it.
Anavex Life Sciences Corp. elsewhere on the record
Companies that share a holder
- Vanguard Capital Management also filed stake reports on 1495 other companies: A10 Networks Inc (Oct 2026), Altisource Portfolio Solutions SA (Oct 2026), Alto Neuroscience Inc (Oct 2026)
- The Vanguard Group also filed stake reports on 2384 other companies: BellRing Brands, Inc. (Sep 2026), CAL-MAINE FOODS INC (Sep 2026), FTAI Aviation Ltd. (Sep 2026)
Watch Anavex Life Sciences Corp.
Get an email when Anavex Life Sciences Corp. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Anavex Life Sciences Corp.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Anavex Life Sciences Corp.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Anavex Life Sciences Corp. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
6 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-11-03 | In | Chief Executive Officer | 8-K, 2026-11-03 | ||
| 2026-11-03 | In | 8-K, 2026-11-03 | |||
| 2026-11-02 | Reported | not named in the filing | 8-K, 2026-11-02 | ||
| 2026-05-15 | Out | Chief Executive Officer | 8-K, 2026-05-15 | ||
| 2026-05-06 | In | Chief Executive Officer | 8-K, 2026-05-06 |
Who leads Anavex Life Sciences Corp., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Executive Officer: Terrie Kellmeyer, appointed (filed 2026-11-03).
New leaders reset buying decisions — get the Full Report on Anavex Life Sciences Corp.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Executive Officer at Anavex Life Sciences Corp., with the record behind each one.
Find candidates like Chief Executive Officer at Anavex Life Sciences Corp.Every change, in the filing's words
Appointed: Terrie Kellmeyer, Chief Executive Officer
On November 1, 2026, the Board of Directors ("Board") of Anavex Life Sciences Corp. ("Anavex" or the "Company"), appointed Terrie Kellmeyer, Ph.D. as the Company's Chief Executive Officer ("CEO") and President effective immediately.
Appointed: Terrie Kellmeyer
Appointment of New Director Also on November 1, 2026, the Board appointed Dr. Kellmeyer to the Board effective immediately and reduced the size of the Board from six to five.
- Dr. Kellmeyer, age 59, has served as the Company's Interim CEO since May 4, 2026.
- Dr. Kellmeyer possesses over 30 years of experience in the pharmaceutical industry and has held executive leadership positions in Clinical Development, Regulatory Affairs, Clinical Operations, and Medical Affairs across multiple therapeutic areas.
- Prior to her appointment as the Company's Interim CEO, she was the Senior Vice President, Clinical Development of the Company from November 2023 to May 2025 and continued to work with the Company as a Senior Advisor until her appointment as Interim CEO.
- Dr. Kellmeyer also served as Executive Vice President, Regulatory Affairs at Aardvark Therapeutics from May 2025 to May 2026, as a consultant at Aardvark Therapeutics from May to June 2026 and continues to serve as a Strategic Advisor to Aardvark Therapeutics.
- Prior to joining Anavex, Dr. Kellmeyer held strategic leadership positions, including Group Vice President of Clinical Development at Acer Therapeutics from August 2021 to November 2023, Head of Global Regulatory Affairs at Madrigal Pharmaceuticals from July 2019 to August 2021 and positions of increasing responsibility at Intercept Pharmaceuticals, Amylin Pharmaceuticals and Gen-Probe.
- Dr. Kellmeyer also served as a consultant to Tunnell Consulting from August 2022 to May 2026 and to i2o Therapeutics from July 2025 to December 2025.
Reported
On October 28, 2026, each of Dr. Jiong Ma, Mr. Gautam Patel and Dr. Adrian Senderowicz resigned from the Board of Directors ("Board") of Anavex Life Sciences Corp. ("Anavex" or the "Company") effective as of October 28, 2026.
- Prior to such resignations, Dr. Ma served as the Chair of the Board and a member of the Audit Committee of the Board, Mr. Patel served as a member of the Audit Committee of the Board and Dr. Senderowicz was not serving on any Board committees.
- As stated in Dr. Ma's resignation letter, Dr. Ma has decided that her views about the Company's strategic direction are not fully aligned with those of the Board and management.
- As stated in Mr. Patel's resignation letter, Mr. Patel has concluded that his personal views regarding the Company's strategy to execute its business plan do not sufficiently align with those of the Board and management.
- As stated in Dr. Senderowicz's resignation letter, Dr. Senderowicz has concluded that his personal views regarding the Company's strategy to execute its business plan do not sufficiently align with those of the Board and management.
Departing: Felix Lauscher, Chief Executive Officer
On May 11, 2026, Felix Lauscher, who had held the title of Chief Operating Officer of Anavex Life Sciences Corp. (the "Company") since March 1, 2026, departed from the Company as part of a broader reorganization of duties at the Company following the appointment of Dr. Terrie Kellmeyer as the Company's Interim Chief Executive Officer.
- During his tenure as Chief Operating Officer and pursuant to his employment agreement, Mr. Lauscher had an annual base salary of $264,000, of which he received a prorated amount for his period of service.
- In addition, he was granted 50,000 stock options, of which 45,833 were immediately forfeited upon his departure and 4,167 of which vested on March 31, 2026 and remain exercisable until August 9, 2026 at a price of $4.69 per share in accordance with his award agreement and the Company's Omnibus Incentive Plan.
- In connection with his departure, in consideration for the execution (and non-revocation) of a general release he has been offered a further two weeks' compensation at his base salary level.
Appointed: Terrie Kellmeyer, Chief Executive Officer
On May 4, 2026, the Board appointed Terrie Kellmeyer, PhD as the Company's Interim Chief Executive Officer.
- Termination of Chief Executive Officer On April 30, 2026, a special committee (the "Special Committee") composed of independent directors of the Board of Directors (the "Board") of Anavex Life Sciences Corp. (the "Company") terminated the employment of Christopher Missling, PhD as the Company's Chief Executive Officer for Cause (as defined in the Employment Agreement, dated as of June 27, 2013, between Dr. Missling and the Company, as amended and restated), effective immediately, for, among other things, conduct that the Special Committee believed was inconsistent with Company policy.
- The Special Committee has also requested that Dr. Missling resign as a member of the Board.
- Dr. Kellmeyer possesses over 30 years of experience in the pharmaceutical industry and has held executive leadership positions in Clinical Development, Regulatory Affairs, Clinical Operations, and Medical Affairs across multiple therapeutic areas.
- Prior to her appointment, she was the Senior Vice President, Clinical Development of the Company from November 2023 to May 2025 and has continued to work with the Company as a Senior Advisor since that date.
- Dr. Kellmeyer has also been acting as Executive Vice President, Regulatory Affairs at Aardvark Therapeutics since May 2025.
Tools for this story
Each opens in a new tab, filled in for Anavex Life Sciences Corp.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.